Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2025, Vol. 39 ›› Issue (5): 139-147.doi: 10.6040/j.issn.1673-3770.0.2024.132

• Review • Previous Articles    

Research progress of IL-35 in allergic rhinitis

ZHANG Ting1, WANG Meilan2, GAO Yingqin2   

  1. 1. Department of Pharmacy, Dali University, Dali 671000, Yunnan, China2. Department of Otorhinolaryngology & Head and Neck Surgery, Kunming Children's Hospital, Kunming 650100, Yunnan, China
  • Published:2025-09-19

PDF (PC)

27

Abstract: Interleukin-35(IL-35)is a member of the IL-12 family and serves as an immunoregulatory factor primarily secreted by immune cells, including regulatory T cells and dendritic cells, It is capable of inducing various types of regulatory cells, such as IL-35-induced regulatory T cells(iTr35), IL-10-producing regulatory B cells(IL-10+Bregs), and IL-35-producing regulatory B cells(IL-35+Bregs), which play significant roles in modulating the immune system across various diseases. Numerous studies have demonstrated that IL-35 is crucial for maintaining immune system homeostasis, regulating inflammatory responses, and suppressing cellular immune responses. Recent studies have found that IL-35 also plays a certain role in the occurrence and development of allergic rhinitis(AR). This article provides an overview of IL-35, summarizes the relevant research progress regarding IL-35 in allergic rhinitis, discusses its potential involvement in the pathogenesis.

Key words: Interleukin 35, Cytokine, Allergic rhinitis, Eosinophils, Immunotherapy

CLC Number: 

  • R765.21
[1] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 106-129. doi:10.3760/cma.j.cn115330-20211228-00828 Subspecialty Group of Rhinology, Editorial Board of Chinese journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery Chinese Medical Association. Chinese guideline for diagnosis and treatment of allergic rhinitis(2022, revision)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 106-129. doi:10.3760/cma.j.cn115330-20211228-00828
[2] Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86): 8-160. doi:10.1111/j.1398-9995.2007.01620.x
[3] Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma(ARIA)guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010, 126(3): 466-476. doi:10.1016/j.jaci.2010.06.047
[4] Wise SK, Damask C, Greenhawt M, et al. A synopsis of guidance for allergic rhinitis diagnosis and management from ICAR 2023[J]. J Allergy Clin Immunol Pract, 2023, 11(3): 773-796. doi:10.1016/j.jaip.2023.01.007
[5] Bro(·overz)ek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)guidelines-2016 revision[J]. J Allergy Clin Immunol, 2017, 140(4): 950-958. doi:10.1016/j.jaci.2017.03.050
[6] Vignali DAA, Kuchroo VK. IL-12 family cytokines: immunological playmakers[J]. Nat Immunol, 2012, 13(8): 722-728. doi:10.1038/ni.2366
[7] Gee K, Guzzo C, Che Mat NF, et al. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders[J]. Inflamm Allergy Drug Targets, 2009, 8(1): 40-52. doi:10.2174/187152809787582507
[8] Su LC, Liu XY, Huang AF, et al. Emerging role of IL-35 in inflammatory autoimmune diseases[J]. Autoimmun Rev, 2018, 17(7): 665-673. doi:10.1016/j.autrev.2018.01.017
[9] Wang Y, Mao Y, Zhang JF, et al. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells[J]. J Cell Mol Med, 2018, 22(2): 1014-1025. doi:10.1111/jcmm.13428
[10] Reza Lahimchi M, Eslami M, Yousefi B. Interleukin-35 and interleukin-37 anti-inflammatory effect on inflammatory bowel disease: application of non-coding RNAs in IBD therapy[J]. Int Immunopharmacol, 2023, 117: 109932. doi:10.1016/j.intimp.2023.109932
[11] Zhang X, Zhang XL, Zhuang LL, et al. Decreased regulatory T-cell frequency and interleukin-35 levels in patients with rheumatoid arthritis[J]. Exp Ther Med, 2018, 16(6): 5366-5372. doi:10.3892/etm.2018.6885
[12] Nicholl MB, Ledgewood CL, Chen XH, et al. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor[J]. Cytokine, 2014, 70(2): 126-133. doi:10.1016/j.cyto.2014.06.020
[13] Li ZX, Zhu L, Zheng H, et al. Serum IL-35 levels is a new candidate biomarker of cancer-related Cachexia in stage IV non-small cell lung cancer[J]. Thorac Cancer, 2022, 13(5): 716-723. doi:10.1111/1759-7714.14307
[14] Long J, Guo HY, Cui SC, et al. IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression[J]. Oncotarget, 2016, 7(29): 45678-45686. doi:10.18632/oncotarget.10141
[15] Dong J, Wong CK, Cai Z, et al. Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells[J]. Allergy, 2015, 70(8): 921-932. doi:10.1111/all.12631
[16] Li Y, Pan XH, Peng X, et al. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma[J]. Inflamm Res, 2015, 64(10): 767-774. doi:10.1007/s00011-015-0858-1
[17] Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin[J]. Proc Natl Acad Sci USA, 1997, 94(22): 12041-12046. doi:10.1073/pnas.94.22.12041
[18] Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169): 566-569. doi:10.1038/nature06306
[19] Choi J, Leung PS, Bowlus C, et al. IL-35 and autoimmunity: a comprehensive perspective[J]. Clin Rev Allergy Immunol, 2015, 49(3): 327-332. doi:10.1007/s12016-015-8468-9
[20] Thompson A, Orr SJ. Emerging IL-12 family cytokines in the fight against fungal infections[J]. Cytokine, 2018, 111: 398-407. doi:10.1016/j.cyto.2018.05.019
[21] Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population[J]. Nat Immunol, 2010, 11(12): 1093-1101. doi:10.1038/ni.1952
[22] Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases[J]. Nature, 2014, 507(7492): 366-370. doi:10.1038/nature12979
[23] Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease[J]. Nat Med, 2014, 20(6): 633-641. doi:10.1038/nm.3554
[24] Haller S, Duval A, Migliorini R, et al. Interleukin-35-producing CD8α+ dendritic cells acquire a tolerogenic state and regulate T cell function[J]. Front Immunol, 2017, 8: 98. doi:10.3389/fimmu.2017.00098
[25] Choi JK, Egwuagu CE. Interleukin 35 regulatory B cells[J]. J Mol Biol, 2021, 433(1): 166607. doi:10.1016/j.jmb.2020.07.019
[26] Collison LW, Delgoffe GM, Guy CS, et al. The composition and signaling of the IL-35 receptor are unconventional[J]. Nat Immunol, 2012, 13(3): 290-299. doi:10.1038/ni.2227
[27] Ye C, Yano H, Workman CJ, et al. Interleukin-35: structure, function and its impact on immune-related diseases[J]. J Interferon Cytokine Res, 2021, 41(11): 391-406. doi:10.1089/jir.2021.0147
[28] Gao P, Su ZZ, Lv XJ, et al. Interluekin-35 in asthma and its potential as an effective therapeutic agent[J]. Mediators Inflamm, 2017, 2017: 5931865. doi:10.1155/2017/5931865
[29] Xie FM, Hu QF, Cai QF, et al. IL-35 inhibited Th17 response in children with allergic rhinitis[J]. ORL J Otorhinolaryngol Relat Spec, 2020, 82(1): 47-52. doi:10.1159/000504197
[30] Kouzaki H, Arikata M, Koji M, et al. Dynamic change of anti-inflammatory cytokine IL-35 in allergen immune therapy for Japanese cedar pollinosis[J]. Allergy, 2020, 75(4): 981-983. doi:10.1111/all.14124
[31] Xie Q, Xu WD, Pan M, et al. Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis[J]. Int Immunopharmacol, 2021, 90: 107231. doi:10.1016/j.intimp.2020.107231
[32] Li YX, Yao LT, Liu SY, et al. Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity[J]. J Investig Med, 2019, 67(3): 707-710. doi:10.1136/jim-2018-000814
[33] Sakkas LI, Mavropoulos A, Perricone C, et al. IL-35: a new immunomodulator in autoimmune rheumatic diseases[J]. Immunol Res, 2018, 66(3): 305-312. doi:10.1007/s12026-018-8998-3
[34] Nakano S, Morimoto S, Suzuki S, et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis[J]. Rheumatology, 2015, 54(8): 1498-1506. doi:10.1093/rheumatology/keu528
[35] Wang W, Li P, Chen YF, et al. A potential immunopathogenic role for reduced IL-35 expression in allergic asthma[J]. J Asthma, 2015, 52(8): 763-771. doi:10.3109/02770903.2015.1038390
[36] Abushouk A, Alkhalaf H, Aldamegh M, et al. IL-35 and IL-37 are negatively correlated with high IgE production among children with asthma in Saudi Arabia[J]. J Asthma, 2022, 59(4): 655-662. doi:10.1080/02770903.2021.1878533
[37] Fogel O, Rivière E, Seror R, et al. Role of the IL-12/IL-35 balance in patients with Sj?gren syndrome[J]. J Allergy Clin Immunol, 2018, 142(1): 258-268.e5. doi:10.1016/j.jaci.2017.07.041
[38] Saeed MH, Kurosh K, Zahra A, et al. Decreased serum levels of IL-27and IL-35 in patients with Graves disease[J]. Arch Endocrinol Metab, 2021, 64(5): 521-527. doi:10.20945/2359-3997000000227
[39] Zhao MN, Gu J, Wang ZC. B cells in Crohn's patients presented reduced IL-35 expression capacity[J]. Mol Immunol, 2020, 118: 124-131. doi:10.1016/j.molimm.2019.12.005
[40] Zhao MM, Song JC, Du SS, et al. Serum IL-35 levels are associated with activity and progression of sarcoidosis[J]. Front Immunol, 2020, 11: 977. doi:10.3389/fimmu.2020.00977
[41] Kouzaki H, Arai Y, Nakamura K, et al. Anti-inflammatory roles of interleukin-35 in the pathogenesis of Japanese cedar pollinosis[J]. Asia Pac Allergy, 2021, 11(3): e34. doi:10.5415/apallergy.2021.11.e34
[42] Bayrak Degirmenci P, Aksun S, Altin Z, et al. Allergic rhinitis and its relationship with IL-10, IL-17, TGF-β, IFN-γ, IL 22, and IL-35[J]. Dis Markers, 2018, 2018: 9131432. doi:10.1155/2018/9131432
[43] Ruan GX, Wen XL, Yuan ZW. Correlation between miR-223 and IL-35 and their regulatory effect in children with allergic rhinitis[J]. Clin Immunol, 2020, 214: 108383. doi:10.1016/j.clim.2020.108383
[44] Yokota M, Suzuki M, Nakamura Y, et al. Cytokine modulation by IL-35 in mice with allergic rhinitis[J]. Am J Rhinol Allergy, 2015, 29(4): 251-256. doi:10.2500/ajra.2015.29.4188
[45] Nie MR, Zeng QX, Xi L, et al. The effect of IL-35 on the expression of nasal epithelial-derived proinflammatory cytokines[J]. Mediators Inflamm, 2021, 2021: 1110671. doi:10.1155/2021/1110671
[46] Huang LG, Zhao M, Luo Q, et al. The role and correlation of IL-35 and type II intrinsic lymphocytes in children with allergic rhinitis[J]. Cell Mol Biol, 2021, 67(2): 127-131. doi:10.14715/cmb/2021.67.2.19
[47] Liu WL, Zeng QX, Wen YH, et al. Inhibited interleukin 35 expression and interleukin 35-induced regulatory T cells promote type II innate lymphoid cell response in allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2021, 126(2): 152-161.e1. doi:10.1016/j.anai.2020.08.005
[48] 尹雪, 任秀敏, 刘春苗, 等. 变应性鼻炎患者IL-35对于Treg/Th17细胞平衡的调控作用[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(3): 213-216. doi: 10.13201/j.issn.1001-1781.2016.03.011
[49] Suzuki M, Yokota M, Nakamura Y, et al. Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis[J]. Allergol Int, 2017, 66(2): 351-356. doi:10.1016/j.alit.2016.08.014
[50] Huang CH, Loo EX, Kuo IC, et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35[J]. J Immunol, 2011, 187(1): 462-471. doi:10.4049/jimmunol.1100259
[51] Kanai K, Park AM, Yoshida H, et al. IL-35 suppresses lipopolysaccharide-induced airway eosinophilia in EBI3-deficient mice[J]. J Immunol, 2017, 198(1): 119-127. doi:10.4049/jimmunol.1600506
[52] Zeng QX, Zeng YH, Tang YQ, et al. Effect of IL-35 on apoptosis, adhesion, migration, and activation of eosinophils in allergic rhinitis[J]. Pediatr Allergy Immunol, 2022, 33(2): e13717. doi:10.1111/pai.13717
[53] Zeng YH, Xiao HQ, Gao SL, et al. Efficacy and immunological changes of sublingual immunotherapy in pediatric allergic rhinitis[J]. World Allergy Organ J, 2023, 16(7): 100803. doi:10.1016/j.waojou.2023.100803
[54] Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens[J]. World Allergy Organ J, 2015, 8(1): 17. doi:10.1186/s40413-015-0063-2
[55] Durham SR, Shamji MH. Allergen immunotherapy: past, present and future[J]. Nat Rev Immunol, 2023, 23(5): 317-328. doi:10.1038/s41577-022-00786-1
[56] Layhadi JA, Eguiluz-Gracia I, Shamji MH. Role of IL-35 in sublingual allergen immunotherapy[J]. Curr Opin Allergy Clin Immunol, 2019, 19(1): 12-17. doi:10.1097/ACI.0000000000000499
[57] Shamji MH, Layhadi JA, Achkova D, et al. Role of IL-35 in sublingual allergen immunotherapy[J]. J Allergy Clin Immunol, 2019, 143(3): 1131-1142.e4. doi:10.1016/j.jaci.2018.06.041
[58] Liu WL, Zeng QX, Luo RZ. Predictors for short-term efficacy of allergen-specific sublingual immunotherapy in children with allergic rhinitis[J]. Mediators Inflamm, 2020, 2020: 1847061. doi:10.1155/2020/1847061
[59] Zhou J, Lu Y, Wu W, et al. Taurine promotes the production of CD4+CD25+FOXP3+ Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model[J]. Allergy Asthma Clin Immunol, 2021, 17(1): 59. doi:10.1186/s13223-021-00562-1
[60] Wu XH, He B, Liu J, et al. Molecular insight into gut microbiota and rheumatoid arthritis[J]. Int J Mol Sci, 2016, 17(3): 431. doi:10.3390/ijms17030431
[61] Maeda Y, Takeda K. Host-microbiota interactions in rheumatoid arthritis[J]. Exp Mol Med, 2019, 51(12): 1-6. doi:10.1038/s12276-019-0283-6
[62] Maeda Y, Takeda K. Role of gut microbiota in rheumatoid arthritis[J]. J Clin Med, 2017, 6(6): 60. doi:10.3390/jcm6060060
[63] Zhou MS, Zhang B, Gao ZL, et al. Altered diversity and composition of gut microbiota in patients with allergic rhinitis[J]. Microb Pathog, 2021, 161(Pt A): 105272. doi:10.1016/j.micpath.2021.105272
[64] 王惟一, 时蕾, 张志玉, 等. 高脂饮食对过敏性鼻炎小鼠致敏影响和肠道菌群改变的研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 21-29. doi:10.6040/j.issn.1673-3770.0.2022.137 WANG Weiyi, SHI Lei, ZHANG Zhiyu, et al. Effects of high fat diet on allergic rhinitis mice and intestinal flora[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 21-29. doi:10.6040/j.issn.1673-3770.0.2022.137
[65] Zhu LB, Xu F, Wan WR, et al. Gut microbial characteristics of adult patients with allergy rhinitis[J]. Microb Cell Fact, 2020, 19(1): 171. doi:10.1186/s12934-020-01430-0
[66] Kaczynska A, Klosinska M, Chmiel P, et al. The crosstalk between the gut microbiota composition and the clinical course of allergic rhinitis: the use of probiotics, prebiotics and bacterial lysates in the treatment of allergic rhinitis[J]. Nutrients, 2022, 14(20): 4328. doi:10.3390/nu14204328
[67] Sahoyama Y, Hamazato F, Shiozawa M, et al. Multiple nutritional and gut microbial factors associated with allergic rhinitis: the hitachi health study[J]. Sci Rep, 2022, 12(1): 3359. doi:10.1038/s41598-022-07398-8
[68] Xue JM, Ma F, An YF, et al. Probiotic extracts ameliorate nasal allergy by inducing interleukin-35-producing dendritic cells in mice[J]. Int Forum Allergy Rhinol, 2019, 9(11): 1289-1296. doi:10.1002/alr.22438
[69] Su XM, Zhang MY, Qi HB, et al. Gut microbiota-derived metabolite 3-idoleacetic acid together with LPS induces IL-35+ B cell generation[J]. Microbiome, 2022, 10(1): 13. doi:10.1186/s40168-021-01205-8
[1] XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.
[2] HUANG Huan, HUA Hongli, DENG Yuqin, JIANG Chengyang, WANG Yuwei, YANG Xinghai. Correlation of allergic rhinitis, tonsil adenoid hypertrophy, and sinusitis in children and analysis of its clinical guiding value [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 34-41.
[3] LIU Yijun, GU Yue, GUAN Dayu, YANG Yucheng, SHEN Yang. The long-term clinical efficacy and safety of vidian neurectomy in refractory allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 42-48.
[4] ZHANG Zhuping, PENG Zican, XIAO Zhenlong, LI Cheng, YU Di, WANG Xinglong, CHEN Wei, Guo Bei. The value of a novel nasal secretion eosinophil cationic protein-myeloperoxidase test paper assay in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 129-134.
[5] CAO Zhengyong, LI Xiaobo. Comparison of the safety and efficacy of short-course postoperative topical glucocorticoid adjuvant therapy for eCRSwNP combined with asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 43-50.
[6] LIU Chang, YANG Jingpu, GAO Yu, WANG Wenjia. Analysis of allergen detection results in children with allergic rhinitis in the Changchun area [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 51-58.
[7] ZHOU Heqing, SHEN Qi. Research progress on biomarkers of traditional Chinese medicine in the treatment of allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 168-176.
[8] ZHANG Jie, NIMA Jizong, XU Xiaodong, ZHOU Jing, LIU Jianmin, LUO Yirui, DU Jintao, BA Luo. Effect of Crocin on Type 2 inflammation in eosinophilic chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 61-67.
[9] WANG Manxian, ZHENG Quan, YANG Liang. Research progress in the treatment of allergic rhinitis with bacterial lysates [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 141-145.
[10] LIU Chang, FANG Hongyan, LIU Xiao, FU Dongna, WANG He, WANG Jing, YANG Jingpu. Analysis of sensitization characteristics of Artemisia pollen in autumn allergic rhinitis in the Changchun area of China [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(5): 13-19.
[11] ZHANG Jie, CHEN Min, SHEN Zhengzheng, WU Yuhua, LIU Yuanhu, SUN Hao, TAN Xinhua, NI Shuren, YANG Shuxun, SHI Xuezheng, NI Xin. Study on the correlation between allergic rhinitis and coronavirus disease-2019 infection and symptoms in children [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 36-42.
[12] ZHU Lang, LIU Zhiqi. Utilization of real-world data from mobile health applications in therapeutic interventions for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 135-139.
[13] ZHANG Jingyi, DONG Xiangyi, MU Yakui, SONG Xicheng. Research progress on pyroptosis in otorhinolaryngology diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 140-148.
[14] ZHANG Lijing, FENG Xiaoxing, LIU Nanxian, ZHAO Huiming, CHEN Yuehua. Graphene cured nasal mask combined with subcutaneous specific immunotherapy of dust mite in patients with dust mite allergic rhinitis application analysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(3): 26-32.
[15] FAN Yongjiang, HUANG Wei, HE Chengshan, SHEN Haitao, XU Zheng, HAO Yanan. Cytokine expression among patients with acute secretory otitis media after SARS-CoV-2 infection [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(2): 1-6.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd